Telix Pharmaceuticals Ltd
TLX
Company Profile
Business description
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
Contact
Sector
Healthcare
Stock type
Industry
Biotechnology
Fiscal Year End
Employees
Telix Pharmaceuticals Ltd News & Analysis
stocks
What we think of the 3 big winners of the ASX 100
Exploring the ASX companies who dominated the market this year
stocks
Ask the analyst: Are Telix's growth prospects priced in?
Telix has come from nowhere to being a $7 billion ASX200 company. Shane Ponraj answers a reader question on its growth outlook and valuation from here.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,557.40 | 11.70 | -0.14% |
| CAC 40 | 7,709.75 | 75.01 | 0.98% |
| DAX 40 | 20,903.39 | 248.00 | 1.20% |
| Dow JONES (US) | 43,487.83 | 334.70 | 0.78% |
| FTSE 100 | 8,505.22 | 113.32 | 1.35% |
| HKSE | 19,584.06 | 61.17 | 0.31% |
| NASDAQ | 19,630.20 | 291.91 | 1.51% |
| Nikkei 225 | 38,451.46 | 121.14 | -0.31% |
| NZX 50 Index | 13,130.43 | 129.76 | 1.00% |
| S&P 500 | 5,996.66 | 59.32 | 1.00% |
| S&P/ASX 200 | 8,310.40 | 16.60 | -0.20% |
| SSE Composite Index | 3,241.82 | 5.79 | 0.18% |